Source: BioSpace

Kalexsyn: Merger of Kalexsyn, Inc. into Dipharma Inc.

Dipharma Francis ("Dipharma"), a global CDMO and a leading manufacturer of APIs and intermediates for generic and contract manufacturing markets, is pleased to announce that Kalexsyn, Inc., a Michigan corporation ("Kalexsyn") acquired in 2018, has been merged into its 100% owner, Dipharma Inc., a Delaware corporation and member of the Dipharma Group, effective January 01, 2022.

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Brian Eklov's photo - CEO of Kalexsyn

CEO

Brian Eklov

CEO Approval Rating

- -/100

Read more